Bio Protocol Raises $6.9M to Power AI-Powered DeSci with Bio V2 and Aubrai
Bio Protocol has secured $6.9 million in strategic funding led by Maelstrom Fund, with participation from Mechanism Capital, Animoca Brands and Presto Labs. The round aims to accelerate its AI-driven DeSci platform by integrating on-chain prediction and credit markets, agent communications and BIO token staking. The updated Bio V2 release introduces Ignition Sales for tokenized IP, the BioXP reward mechanism and decentralized frameworks for early-stage research. Each milestone is immutably recorded on-chain, ensuring traceability and contributor recognition.
In August 2025, Bio Protocol launched Aubrai, its first BioAgent developed with VitaDA. Aubrai has raised $900,000, produced over 1,000 blockchain-based scientific hypotheses and spurred AUBRAI token adoption. CEO Paul Kohlhaas says the platform can cut drug discovery timelines from decades to months. These developments underscore the convergence of AI, blockchain and DeSci, positioning Bio Protocol’s model to democratize R&D and attract further crypto investment.
Bullish
This funding round and product launches signal strong momentum for Bio Protocol’s ecosystem. Securing $6.9M and deploying Bio V2 with on-chain fundraising, token staking and a live BioAgent (Aubrai) should boost investor confidence and token demand for BIO and AUBRAI. In the short term, expect positive price action as traders react to the funding news and new platform features. Over the long term, the convergence of AI, blockchain and decentralized science offers sustainable growth potential, likely supporting continued interest and higher valuations in the DeSci token market.